Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

An ideal Mounjaro diet plan should focus on nutrient-dense foods, such as fruits, vegetables, whole grains, lean proteins, ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

A Chinese start-up’s new artificial intelligence program took the top spot in Apple’s app store, threatening U.S. dominance ...

RFG Advisory LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 13.4% in the fourth quarter, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...